Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Ferrero

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|October 3, 1999
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)P Viens, T Palangié, M Janvier, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2018
5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French studyA Ploquin, B Pistilli, E Tresch, et al.
British Journal of Cancer|February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO groupI Ray-Coquard, B Weber, J Cretin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancerA Gonçalves, J-Y Pierga, J-M Ferrero, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patientsE Jacquet, A Lardy-Cléaud, B Pistilli, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosisT Gaillard, M Carton, A Mailliez, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
British Journal of Cancer|April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutationJ-S Frenel, A Lusque, S Delaloge, et al.
ESMO Open|May 13, 2021
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life databaseM Carausu, M Carton, A Darlix, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|October 3, 1999
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)P Viens, T Palangié, M Janvier, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2018
5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French studyA Ploquin, B Pistilli, E Tresch, et al.
British Journal of Cancer|February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO groupI Ray-Coquard, B Weber, J Cretin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancerA Gonçalves, J-Y Pierga, J-M Ferrero, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patientsE Jacquet, A Lardy-Cléaud, B Pistilli, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosisT Gaillard, M Carton, A Mailliez, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
British Journal of Cancer|April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutationJ-S Frenel, A Lusque, S Delaloge, et al.
ESMO Open|May 13, 2021
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life databaseM Carausu, M Carton, A Darlix, et al.
Pageof 8